Hints and tips:
Related Special Reports
...Other drugmakers could still “win” the race in the rapidly growing obesity market dominated by Novo Nordisk and Eli Lilly, according to the chief executive of biotech company Zealand Pharma....
...A new venture, led by the founder of a biotech group that was sold to Sanofi for up to $1.45bn in 2021, has won £48mn in funding for research into cancer treatments using machine learning and genetically...
...AstraZeneca has also said it is interested in doing deals with Chinese biotechs....
...AstraZeneca has acquired oncology biotech Fusion Pharmaceuticals for $2.4bn to build its expertise and challenge Swiss company Novartis in the developing field of a more targeted form of radiotherapy....
...It has also made several small acquisitions in the past year, acquiring biotech companies working in new areas including cell therapies, obesity drugs and radiopharmaceuticals....
...AstraZeneca has agreed to buy oncology biotech Fusion Pharmaceuticals for $2.4bn, as it builds its capacity in a developing field of cancer care....
...It has 178 prospects at various stages of development; it has been striking a series of deals, including last month’s $2.4bn agreement to buy Canadian biotech Fusion Pharmaceuticals aimed at bolstering its...
...The deal is expected to close in the first quarter of next year, AstraZeneca said....
...Earlier this year, Pascal Soriot, AstraZeneca’s chief executive, expressed excitement about the “explosion” of biotech companies and innovative science in China after a tour of the country....
...The agreement is part of AstraZeneca’s ambitious plans to replace traditional chemotherapy with a new generation of targeted drugs....
...It supplied ingredients for AstraZeneca’s Covid-19 vaccine. Growth is slowing as vaccine demand falls. Wuxi Biologics is likely to miss its original sales target for the year by about $400mn....
...The £64bn company has long lagged behind £168bn Anglo-Swedish rival AstraZeneca, with investors raising questions over GSK’s pipeline of products and its growth plans....
...Roche and AstraZeneca have already struck deals to buy or license early stage weight-loss drugs....
...I unwittingly contributed to a broad bust in UK biotech stocks in the late 1990s by exposing the inaccuracy of claims made by flagship company British Biotech. Its drugs did not work....
...US biotech Viking Therapeutics’ shares more than doubled after trial data for the company’s weight-loss drug outperformed existing treatments from drugmakers Novo Nordisk and Eli Lilly....
...Companies including UK’s AstraZeneca and Swiss group Roche have recently acquired or licensed weight-loss drugs in an effort to enter a market that analysts expected would exceed $100bn by 2030....
...Last year, Richard and his wife Amanda relocated to Cambridge when she got a job with a biotech company in one of the city’s science parks....
...Other big drugmakers were likely to be examining potential deals to secure obesity medicines, said Field of Barclays, especially those that sold diabetes drugs, such as AstraZeneca and Sanofi, or cardio-metabolic...
...Pascal Soriot, AstraZeneca’s chief executive, toured China earlier this year and returned excited about the potential for investing in Chinese biotech, including through acquisitions and partnerships....
...This month Novo Nordisk signed deals worth up to $1bn with US biotechs, following several acquisitions last year....
...Sector darling AstraZeneca is on over 15. Roche’s new-ish chief executive Thomas Schinecker has admitted that drug hit rates have been low....
...Some of the examples they choose will provoke a head-shake of recognition: the biotech customer service representative forced to switch between “15 applications and 20 windows on the 13-inch screen of her...
...The AstraZeneca vaccine has fallen far behind its mRNA rivals from BioNTech/Pfizer and Moderna....
...to biotechs without revenue....
...Roche and AstraZeneca have acquired or signed licensing deals with biotechs developing weight-loss treatments in the past year....
International Edition